Doxy-PEP is a single two hundred milligram dose of doxycycline taken after condomless sex, intended to prevent bacterial sexually transmitted infections before they establish. It is a recent addition to prevention and sits in a different category from PrEP: it targets treatable bacterial infections rather than a lifelong virus, and the evidence base is younger.
How does it work?
Doxycycline is a tetracycline antibiotic that blocks bacterial protein synthesis by binding to the ribosome. Bacteria that cannot make proteins cannot multiply. Taking a dose shortly after exposure means the drug is present while any transmitted organisms are still few in number and have not yet established themselves in the mucosal tissue, so they are cleared before an infection develops.
Which infections does it target?
Chlamydia, syphilis and gonorrhoea. The effect is strong against the first two and considerably weaker against gonorrhoea, because tetracycline resistance is already widespread in Neisseria gonorrhoeae. It has no effect on HIV, herpes, HPV, hepatitis or mpox, none of which are susceptible to doxycycline.
Where does the evidence come from?
The main trial was conducted in San Francisco and Seattle among men who have sex with men and trans women who were either taking PrEP or living with HIV. It found around a two-thirds reduction in bacterial sexually transmitted infections overall, with the effect on chlamydia and syphilis far larger than on gonorrhoea. A French study reached broadly similar conclusions. A trial in cisgender women in Kenya did not show benefit, and the reasons for that difference are still debated, with adherence and tissue drug levels both proposed.
How is it different from PrEP?
PrEP prevents a virus with no cure, taken in advance, with an established evidence base spanning more than a decade. Doxy-PEP prevents bacterial infections that are curable with antibiotics, taken afterwards, with a few years of data. The trade-off calculation is therefore different: the benefit is reducing infections that would otherwise be treated, weighed against the population-level cost of more antibiotic use.
Why is it not simply given to everyone?
Because of antimicrobial resistance. Widespread use of a single antibiotic exerts selection pressure not only on the target organisms but on everything else living in the body, including gut bacteria and skin organisms such as Staphylococcus aureus. This is the central tension in the debate about doxy-PEP, and it is why services that offer it do so with specific eligibility criteria rather than as a general offer.
Is it available in the UK?
Availability has been developing and varies by service. UK guidance has been more cautious than in some other countries, partly because of the resistance concern and partly because gonorrhoea rates matter more here than the infections doxycycline handles best. Ask your own clinic what is available locally rather than assuming, since the position continues to move.
What is doxy-PrEP?
A separate approach where doxycycline is taken daily rather than after each exposure. It has been studied and produces protection, but daily antibiotic exposure raises the resistance concerns considerably further, and it is not the approach being implemented in the UK.
What should you know before considering it?
That it is an addition to screening and vaccination rather than a replacement for either. That it does nothing for HIV, which is what PrEP is for. That the dose has to be taken within a limited window after sex. And that it is a genuine antibiotic with genuine side effects and interactions, which the next articles cover.
Who was it studied in?
Gay and bisexual men, other men who have sex with men, and trans women, in each case either taking PrEP or living with HIV. That is a narrow population, and it is why current recommendations are framed around it rather than being general. Extending conclusions beyond the group studied is exactly what the Kenyan trial in cisgender women cautions against.
How long has it been available?
The key results emerged in the early 2020s, which makes this a recent intervention by the standards of sexual health. PrEP by comparison has more than a decade of use behind it. That difference in maturity is worth holding in mind when weighing how confidently anything here can be stated.
What is the practical version?
One tablet, taken as soon as possible after condomless sex and within seventy-two hours, with a full glass of water. It reduces your chance of picking up chlamydia and syphilis considerably, gonorrhoea somewhat, and nothing else at all.